AC Immune shareholders elect Tom Graney to board

Tom Graney’s board appointment runs through the end of AC Immune’s 2027 Annual General Meeting.

Rhea-AI Filing Summary

AC Immune SA (ACIU) shareholders elected Tom Graney to the Board of Directors at an Extraordinary General Meeting held October 2, 2026. His term runs until the end of the Annual General Meeting 2027. AC Immune said the meeting minutes would be published on its website within 15 days.

Filing Explained

This 6-K becomes part of AC Immune’s listed Form F-3 and Form S-8 registration statements from the filing date, so its election results are included in those filings unless later documents or reports supersede them.

Key Terms

Extraordinary General Meeting, incorporated by reference, foreign private issuer

3 terms

Extraordinary General Meeting regulatory

"held an Extraordinary General Meeting"

incorporated by reference regulatory

"shall be deemed to be incorporated by reference"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who did ACIU shareholders elect to the board?

AC Immune SA shareholders elected Tom Graney as a member of the Board of Directors at the Extraordinary General Meeting on October 2, 2026. His term lasts until the end of the Annual General Meeting 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 08:02 AM Accepted by SEC EDGAR 10/02/2026 - 08:02 AM Learn about SEC filing dates

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

​

For the month of October, 2026

​

Commission file number: 001-37891

​

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

​

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F ☒     Form 40-F ☐

​

​

​

​

On October 2, 2026, AC Immune SA (“AC Immune”) held an Extraordinary General Meeting. The final result of the agenda item submitted to a vote of the shareholders is set out below and further details will be provided in the minutes which will be published on AC Immune’s website (https://ir.acimmune.com/governance) within 15 days:

Agenda Item: Election of a Member of the Board of Directors

AC Immune shareholders approved the election of Tom Graney as Member of the Board of Directors until the end of the Annual General Meeting 2027.

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​	​	​
​	AC IMMUNE SA
​	​
​	By:	/s/ Martin Zuegel
​	​	Name:  Martin Zuegel
​	​	Title:    Interim Chief Executive Officer
​	​	​
​	​	​
​	By:	/s/ Christopher Roberts
​	​	Name:  Christopher Roberts
​	​	Title:    Chief Financial Officer
​	​	​
Date:     October 2, 2026	​	​

​

​